Physician profile
Muhammad Rizvi
NPI 1346277555
$2,808.49
in general payments reported to CMS, 2019-2025
14 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $28.09 · 2021: $11.92 · 2022: $99.99 · 2023: $1,949 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,713 · Travel and Lodging: $603 · Food and Beverage: $97.90 · Education: $15.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,712.50 |
| Travel and Lodging | $602.61 |
| Food and Beverage | $97.90 |
| Education | $15.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,855.33 | 2023 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $584.90 | 2019-2025 | Opdivo |
| Incyte Corporation | $99.99 | 2022 | |
| Astellas Pharma US INC | $59.16 | 2019 | |
| Genentech USA, INC. | $51.14 | 2019 | |
| Pfizer INC. | $29.41 | 2019-2020 | |
| Janssen Biotech, INC. | $25.92 | 2019 | |
| Merck Sharp & Dohme LLC | $24.97 | 2019-2020 | |
| Abbvie INC. | $22.08 | 2019 | |
| Verastem, INC. | $15.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2019 | |
| Seagen INC. | $13.64 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.